Trade

with

Catalyst Pharmaceutical Partners Inc
(NASDAQ: CPRX)
AdChoices
2.55
-0.13
-4.85%
After Hours :
-
-
-

Open

2.75

Previous Close

2.68

Volume (Avg)

400.94k (1.34M)

Day's Range

2.52-2.79

52Wk Range

1.29-3.49

Market Cap.

180.01M

Dividend Rate ( Yield )

-

Beta

0.84

Shares Outstanding

67.17M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -12.15M

    • Market Cap.

    • 180.01M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.84

    • Forward P/E

    • -9.57

    • Price/Sales

    • -

    • Price/Book Value

    • 4.37

    • Price/Cash flow

    • -11.98

      • EBITDA

      • -10.29M

      • Return on Capital %

      • -48.83

      • Return on Equity %

      • -55.95

      • Return on Assets %

      • -48.83

      • Book Value/Share

      • 0.61

      • Shares Outstanding

      • 67.17M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 7.50

        • Credit Rating

        • -

        • Analysts

        • 4

        • EPS Estimate

        • -0.28

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 0.00

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 64.72

            • Pre-Tax Margin

            • -

            • 13.77

            • Net Profit Margin

            • -

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 19.39

              • 1.52

              • Quick Ratio

              • 19.04

              • 0.87

              • Interest Coverage

              • -

              • 6.77

              • Leverage Ratio

              • 1.12

              • 1.91

              • Book Value/Share

              • 0.61

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -9.41

                • 65.36

                • P/E Ratio 5-Year High

                • -14.02

                • 237.47

                • P/E Ratio 5-Year Low

                • -1.42

                • 19.71

                • Price/Sales Ratio

                • -

                • 3.63

                • Price/Book Value

                • 4.00

                • 3.39

                • Price/Cash Flow Ratio

                • -11.98

                • 21.83

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -55.95

                        (-78.10)

                      • 7.86

                        (9.58)

                      • Return on Assets %

                        (5-Year Average)

                      • -48.83

                        (-65.90)

                      • 4.14

                        (5.54)

                      • Return on Capital %

                        (5-Year Average)

                      • -55.95

                        (-78.10)

                      • 5.59

                        (7.66)

                      • Income/Employee

                      • -

                      • 27.79k

                      • Inventory Turnover

                      • -

                      • 1.80

                      • Asset Turnover

                      • -

                      • 0.38

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -10.31M
                      Operating Margin
                      -
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -11.98
                      Ownership

                      Institutional Ownership

                      33.28%

                      Top 10 Institutions

                      28.70%

                      Mutual Fund Ownership

                      14.01%

                      Float

                      77.07%

                      5% / Insider Ownership

                      10.46%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • AST Federated Aggressive Growth

                      •  

                        1,613,500

                      • 0.00

                      • 2.40

                      • Federated Kaufmann Small Cap Fund

                      •  

                        1,502,600

                      • -3.99

                      • 2.24

                      • Franklin Biotechnology Discovery Fund

                      •  

                        914,000

                      • 16.82

                      • 1.36

                      • Vanguard Total Stock Mkt Idx

                      •  

                        898,480

                      • 0.00

                      • 1.34

                      • Vanguard Extended Market Index Fund

                      •  

                        646,160

                      • 0.00

                      • 0.96

                      • Vanguard Instl Total Stock Market Index

                      •  

                        276,282

                      • 0.00

                      • 0.41

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        212,099

                      • 0.00

                      • 0.32

                      • iShares Micro-Cap

                      •  

                        179,415

                      • 0.00

                      • 0.20

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Federated Global Inv Mgmt Corp

                      •  

                        3,185,000

                      • +87.13%

                      • 4.74

                      • Baker Bros Advisors LLC

                      •  

                        2,223,053

                      • +290.11%

                      • 3.31

                      • Orbimed Advisors, LLC

                      •  

                        1,895,000

                      • 0.00%

                      • 2.82

                      • Vanguard Group, Inc.

                      •  

                        1,788,642

                      • +9.41%

                      • 2.66

                      • Opaleye Management Inc

                      •  

                        1,378,584

                      • 0.00%

                      • 2.05

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Drug Manufacturers – Specific & Generic

                      Type

                      Distressed

                      Style

                      Small Growth

                      Catalyst Pharmaceutical Partners, Inc. was incorporated in Delaware in July 2006. The Company is a development-stage specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting ra...morere (orphan) neurological diseases and disorders, including Lambert-Eaton Myasthenic Syndrome (LEMS) and infantile spasms. It has three pharmaceutical products in development namely Firdapse(tm), CPP-115 and CPP-109. In October 2012, the Company licensed the North American rights to Firdapse(tm), a proprietary form of amifampridine phosphate, or chemically known as 3,4-diaminopyridine phosphate, from BioMarin Pharmaceutical Inc. (BioMarin). CPP-115 is in the early stages of developing CPP-115, a GABA aminotransferase inhibitor that, based on its pre-clinical studies to da...morete, it believe is a more potent form of vigabatrin, but may have fewer side effects than those associated with vigabatrin. CPP-109 was evaluated for the treatment of cocaine addiction. An academic investigator proof-of-concept study evaluating the use of CPP-109 for the treatment of Tourette syndrome is currently ongoing. The Company also competes against biotechnology companies, universities, government agencies, and other research institutions in the development of substance abuse treatments, technologies and processes. The pharmaceutical industry is intensely competitive, and any product candidate developed or licensed by the Company would likely compete with existing drugs and therapies. In the United States, drugs are subject to rigorous regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations, as well as other federal and state statutes.lessless

                      Key People

                      Patrick J. McEnany

                      CEO/Chairman of the Board/Director/President/Co-Founder

                      Dr. Hubert E. Huckel,M.D.

                      Director/Co-Founder

                      Alicia Grande

                      CFO/Chief Accounting Officer/Treasurer/Vice President

                      M. Douglas Winship

                      Vice President, Divisional

                      Dr. Bernardino Mosquera, M.D.

                      Vice President, Divisional

                      • Catalyst Pharmaceutical Partners Inc

                      • 355 Alhambra Circle

                      • Coral Gables, FL 33134

                      • USA.Map

                      • Phone: +1 305 529-2522

                      • Fax: +1 305 529-0933

                      • catalystpharma.com

                      Incorporated

                      2006

                      Employees

                      7

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: